Status:
UNKNOWN
Metadherin mRNA Expression in Bladder Cancer
Lead Sponsor:
Assiut University
Conditions:
Bladder Cancer
Eligibility:
All Genders
30-80 years
Brief Summary
The study aims to study alterations of MTDH gene expression in the serum of bladder cancer patients compared to control group to evaluate its role as a marker for diagnosis. ,to compare the diagnosti...
Detailed Description
Urinary bladder cancer (BC) is the ninth most common cancer worldwide. It is the fifth most common malignancy in males and seventeenth most common in females. In Egypt, bladder cancer represents a ma...
Eligibility Criteria
Inclusion
- Males and females.
- 30-80 years old.
- patients with bladder cancer not receiving any treatment
Exclusion
- patients taking chemotherapy or radiotherapy.
- History of other malignancy.
- History of autoimmune diseases.
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04286672
Start Date
December 1 2020
End Date
January 1 2022
Last Update
September 29 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.